metformin has been researched along with Abdominal Aortic Aneurysm in 26 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Multiple observational studies have associated metformin prescription with reduced progression of abdominal aortic aneurysm (AAA)." | 9.41 | Protocol for the Metformin Aneurysm Trial (MAT): a placebo-controlled randomised trial testing whether metformin reduces the risk of serious complications of abdominal aortic aneurysm. ( Arnott, C; Bown, M; Golledge, J; Jones, G; Li, Q; Monaghan, H; Morris, D; Moxon, J; Neal, B; Norman, R; Roake, J, 2021) |
| "A meta-analysis of the association between metformin prescription and abdominal aortic aneurysm (AAA) growth and events (rupture or surgical repair) was performed." | 9.12 | Editor's Choice - Association Between Metformin Prescription and Abdominal Aortic Aneurysm Growth and Clinical Events: a Systematic Review and Meta-Analysis. ( Golledge, J; Moxon, J; Phie, J; Singh, TP; Thanigaimani, S; Unosson, J; Wanhainen, A, 2021) |
| "Type 2 diabetes mellitus (T2DM) patients have a lower risk of abdominal aortic aneurysm (AAA) and its comorbidities, which might be associated with the usage of metformin." | 9.12 | The Protective Effect of Metformin on Abdominal Aortic Aneurysm: A Systematic Review and Meta-Analysis. ( Cai, Z; Heng, Z; Lu, Y; Wei, J; Yuan, Z, 2021) |
| "Metformin therapy has previously been associated with reduced abdominal aortic aneurysm growth rate in diabetic patients and shown to suppress the formation and progression of abdominal aortic aneurysm in normoglycemic mice." | 8.12 | Metformin therapy is not associated with the lower prevalence of ascending aortic aneurysm in diabetic patients. ( Björck, HM; Franco-Cereceda, A; Ntika, S; Olsson, C; Vignac, M, 2022) |
| "Recent reports suggest that the negative association between diabetes mellitus and abdominal aortic aneurysm (AAA) may be driven by metformin, the world's most common antidiabetic drug rather than diabetes per se." | 8.02 | Metformin Prescription Associated with Reduced Abdominal Aortic Aneurysm Growth Rate and Reduced Chemokine Expression in a Swedish Cohort. ( Bjarnegård, N; De Basso, R; Gottsäter, A; Mani, K; Unosson, J; Wågsäter, D; Wanhainen, A; Welander, M, 2021) |
| "Epidemiological evidence suggests that the antidiabetic drug metformin (MET) can also inhibit abdominal aortic aneurysm (AAA) formation." | 8.02 | Metformin Inhibits Abdominal Aortic Aneurysm Formation through the Activation of the AMPK/mTOR Signaling Pathway. ( Fan, Y; He, J; Hu, X; Li, N; Liu, C; Zhao, X, 2021) |
| "Metformin is a commonly used drug in diabetes mellitus treatment." | 8.02 | Association of Metformin and Abdominal Aortic Aneurysm Repair Outcomes. ( Chabowski, M; Kobecki, J; Laskowska, A; Świątkowski, F; Turowicz, A; Wojciechowski, J, 2021) |
| "We sought to examine the progression from abdominal aortic aneurysm (AAA) diagnosis to surgery and death among diabetics with and without exposure to metformin as well as non-diabetics." | 7.96 | Association between metformin and abdominal aortic aneurysm in diabetic and non-diabetic US veterans. ( Cummings, TH; Hardin, JW; Magagnoli, J; Sutton, SS, 2020) |
| "Metformin in diabetics at-risk for abdominal aortic aneurysm or diagnosed with abdominal aortic aneurysm does not seem to alter the peripheral inflammatory environment." | 7.88 | Metformin does not reduce inflammation in diabetics with abdominal aortic aneurysm or at high risk of abdominal aortic aneurysm formation. ( Fajardo, A; Green, LA; Gupta, AK; Gutwein, AR; Kenyon, B; Motaganahalli, RL; Murphy, MP; Wang, SK, 2018) |
| "Using nationwide Danish registry data, we performed a nested case-control study on the association between long-term use of metformin and ruptured abdominal aortic aneurysm (RAAA)." | 7.85 | Metformin treatment does not affect the risk of ruptured abdominal aortic aneurysms. ( Hallas, J; Kristensen, KL; Lindholt, JS; Pottegård, A; Rasmussen, LM, 2017) |
| "It has been suggested that diabetes medications, such as metformin, may have effects that inhibit abdominal aortic aneurysm (AAA) growth." | 7.85 | Association between metformin prescription and growth rates of abdominal aortic aneurysms. ( Anderson, G; Bourke, B; Bourke, M; Buckenham, T; Dear, A; Golledge, J; Jenkins, J; Jones, R; Moxon, J; Norman, PE; Pinchbeck, J; Rowbotham, S, 2017) |
| "Currently there is no drug therapy for abdominal aortic aneurysm (AAA) and most previous investigations have focused on imaging rather than clinical outcomes." | 5.51 | Editor's Choice - Metformin Prescription is Associated with a Reduction in the Combined Incidence of Surgical Repair and Rupture Related Mortality in Patients with Abdominal Aortic Aneurysm. ( Bourke, B; Bourke, M; Golledge, J; Jenkins, J; Jones, R; Morris, DR; Moxon, JV; Norman, PE; Pinchbeck, J; Rowbotham, S, 2019) |
| "Multiple observational studies have associated metformin prescription with reduced progression of abdominal aortic aneurysm (AAA)." | 5.41 | Protocol for the Metformin Aneurysm Trial (MAT): a placebo-controlled randomised trial testing whether metformin reduces the risk of serious complications of abdominal aortic aneurysm. ( Arnott, C; Bown, M; Golledge, J; Jones, G; Li, Q; Monaghan, H; Morris, D; Moxon, J; Neal, B; Norman, R; Roake, J, 2021) |
| "A meta-analysis of the association between metformin prescription and abdominal aortic aneurysm (AAA) growth and events (rupture or surgical repair) was performed." | 5.12 | Editor's Choice - Association Between Metformin Prescription and Abdominal Aortic Aneurysm Growth and Clinical Events: a Systematic Review and Meta-Analysis. ( Golledge, J; Moxon, J; Phie, J; Singh, TP; Thanigaimani, S; Unosson, J; Wanhainen, A, 2021) |
| "Type 2 diabetes mellitus (T2DM) patients have a lower risk of abdominal aortic aneurysm (AAA) and its comorbidities, which might be associated with the usage of metformin." | 5.12 | The Protective Effect of Metformin on Abdominal Aortic Aneurysm: A Systematic Review and Meta-Analysis. ( Cai, Z; Heng, Z; Lu, Y; Wei, J; Yuan, Z, 2021) |
| "To assess the association of metformin prescription with the risk of aortic aneurysm, aortic aneurysm events and the enlargement of abdominal aortic aneurysm (AAA)." | 5.01 | Metformin prescription and aortic aneurysm: systematic review and meta-analysis. ( Cao, S; Chen, T; Durgahee, MSA; Jiang, D; Wang, J; Wang, K; Wang, R; Wei, X; Yu, X, 2019) |
| "Metformin therapy has previously been associated with reduced abdominal aortic aneurysm growth rate in diabetic patients and shown to suppress the formation and progression of abdominal aortic aneurysm in normoglycemic mice." | 4.12 | Metformin therapy is not associated with the lower prevalence of ascending aortic aneurysm in diabetic patients. ( Björck, HM; Franco-Cereceda, A; Ntika, S; Olsson, C; Vignac, M, 2022) |
| "Recent reports suggest that the negative association between diabetes mellitus and abdominal aortic aneurysm (AAA) may be driven by metformin, the world's most common antidiabetic drug rather than diabetes per se." | 4.02 | Metformin Prescription Associated with Reduced Abdominal Aortic Aneurysm Growth Rate and Reduced Chemokine Expression in a Swedish Cohort. ( Bjarnegård, N; De Basso, R; Gottsäter, A; Mani, K; Unosson, J; Wågsäter, D; Wanhainen, A; Welander, M, 2021) |
| "Epidemiological evidence suggests that the antidiabetic drug metformin (MET) can also inhibit abdominal aortic aneurysm (AAA) formation." | 4.02 | Metformin Inhibits Abdominal Aortic Aneurysm Formation through the Activation of the AMPK/mTOR Signaling Pathway. ( Fan, Y; He, J; Hu, X; Li, N; Liu, C; Zhao, X, 2021) |
| "Metformin is a commonly used drug in diabetes mellitus treatment." | 4.02 | Association of Metformin and Abdominal Aortic Aneurysm Repair Outcomes. ( Chabowski, M; Kobecki, J; Laskowska, A; Świątkowski, F; Turowicz, A; Wojciechowski, J, 2021) |
| "We sought to examine the progression from abdominal aortic aneurysm (AAA) diagnosis to surgery and death among diabetics with and without exposure to metformin as well as non-diabetics." | 3.96 | Association between metformin and abdominal aortic aneurysm in diabetic and non-diabetic US veterans. ( Cummings, TH; Hardin, JW; Magagnoli, J; Sutton, SS, 2020) |
| "Metformin in diabetics at-risk for abdominal aortic aneurysm or diagnosed with abdominal aortic aneurysm does not seem to alter the peripheral inflammatory environment." | 3.88 | Metformin does not reduce inflammation in diabetics with abdominal aortic aneurysm or at high risk of abdominal aortic aneurysm formation. ( Fajardo, A; Green, LA; Gupta, AK; Gutwein, AR; Kenyon, B; Motaganahalli, RL; Murphy, MP; Wang, SK, 2018) |
| "Using nationwide Danish registry data, we performed a nested case-control study on the association between long-term use of metformin and ruptured abdominal aortic aneurysm (RAAA)." | 3.85 | Metformin treatment does not affect the risk of ruptured abdominal aortic aneurysms. ( Hallas, J; Kristensen, KL; Lindholt, JS; Pottegård, A; Rasmussen, LM, 2017) |
| "It has been suggested that diabetes medications, such as metformin, may have effects that inhibit abdominal aortic aneurysm (AAA) growth." | 3.85 | Association between metformin prescription and growth rates of abdominal aortic aneurysms. ( Anderson, G; Bourke, B; Bourke, M; Buckenham, T; Dear, A; Golledge, J; Jenkins, J; Jones, R; Moxon, J; Norman, PE; Pinchbeck, J; Rowbotham, S, 2017) |
| "Metformin prescription was associated with a 28% reduction in AAA occurrence, while SU and TZD were associated with a 18% decrease in AAA risk." | 2.66 | Abdominal aortic aneurysm: a review on the role of oral antidiabetic drugs. ( Mansilha, A; Oliveira-Pinto, J; Ribeiro-Silva, M, 2020) |
| "Metformin use was more common in the AAA group with no growth (P <0." | 1.72 | Optimal Timing of Surveillance Ultrasounds in Small Aortic Aneurysms. ( Caputo, FJ; Harris, D; Kirksey, L; Lyden, SP; Rowse, JW; Smolock, CJ, 2022) |
| "Currently there is no drug therapy for abdominal aortic aneurysm (AAA) and most previous investigations have focused on imaging rather than clinical outcomes." | 1.51 | Editor's Choice - Metformin Prescription is Associated with a Reduction in the Combined Incidence of Surgical Repair and Rupture Related Mortality in Patients with Abdominal Aortic Aneurysm. ( Bourke, B; Bourke, M; Golledge, J; Jenkins, J; Jones, R; Morris, DR; Moxon, JV; Norman, PE; Pinchbeck, J; Rowbotham, S, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (30.77) | 24.3611 |
| 2020's | 18 (69.23) | 2.80 |
| Authors | Studies |
|---|---|
| Thanigaimani, S | 1 |
| Singh, TP | 1 |
| Unosson, J | 3 |
| Phie, J | 1 |
| Moxon, J | 3 |
| Wanhainen, A | 4 |
| Golledge, J | 4 |
| Lareyre, F | 4 |
| Lê, CD | 1 |
| Amrani, S | 1 |
| Raffort, J | 4 |
| Vignac, M | 1 |
| Ntika, S | 1 |
| Olsson, C | 1 |
| Franco-Cereceda, A | 1 |
| Björck, HM | 1 |
| Guo, J | 1 |
| Wang, Z | 1 |
| Xue, M | 1 |
| Mi, L | 1 |
| Zhao, M | 1 |
| Ma, C | 1 |
| Wu, J | 1 |
| Han, X | 1 |
| Rowse, JW | 1 |
| Harris, D | 1 |
| Kirksey, L | 1 |
| Smolock, CJ | 1 |
| Lyden, SP | 1 |
| Caputo, FJ | 1 |
| Arnott, C | 1 |
| Monaghan, H | 1 |
| Norman, R | 1 |
| Morris, D | 1 |
| Li, Q | 1 |
| Jones, G | 1 |
| Roake, J | 1 |
| Bown, M | 1 |
| Neal, B | 1 |
| Li, R | 3 |
| Liu, Y | 3 |
| Jiang, J | 3 |
| Hassen-Khodja, R | 1 |
| Jean-Baptiste, E | 1 |
| Dalman, RL | 3 |
| Mani, K | 3 |
| Modarai, B | 1 |
| Sutton, SS | 1 |
| Magagnoli, J | 1 |
| Cummings, TH | 1 |
| Hardin, JW | 1 |
| Ribeiro-Silva, M | 1 |
| Oliveira-Pinto, J | 1 |
| Mansilha, A | 1 |
| Wågsäter, D | 1 |
| Bjarnegård, N | 1 |
| De Basso, R | 1 |
| Welander, M | 1 |
| Gottsäter, A | 2 |
| He, J | 1 |
| Li, N | 1 |
| Fan, Y | 1 |
| Zhao, X | 1 |
| Liu, C | 1 |
| Hu, X | 1 |
| Turowicz, A | 1 |
| Kobecki, J | 1 |
| Laskowska, A | 1 |
| Wojciechowski, J | 1 |
| Świątkowski, F | 1 |
| Chabowski, M | 1 |
| Yuan, Z | 1 |
| Heng, Z | 1 |
| Lu, Y | 1 |
| Wei, J | 1 |
| Cai, Z | 1 |
| Kristensen, KL | 1 |
| Pottegård, A | 1 |
| Hallas, J | 1 |
| Rasmussen, LM | 1 |
| Lindholt, JS | 1 |
| Pinchbeck, J | 2 |
| Anderson, G | 1 |
| Rowbotham, S | 2 |
| Jenkins, J | 2 |
| Bourke, M | 2 |
| Bourke, B | 2 |
| Dear, A | 1 |
| Buckenham, T | 1 |
| Jones, R | 2 |
| Norman, PE | 2 |
| Hinchliffe, RJ | 1 |
| Wang, SK | 1 |
| Green, LA | 1 |
| Gutwein, AR | 1 |
| Kenyon, B | 1 |
| Motaganahalli, RL | 1 |
| Fajardo, A | 1 |
| Gupta, AK | 1 |
| Murphy, MP | 1 |
| Morris, DR | 1 |
| Moxon, JV | 1 |
| Itoga, NK | 1 |
| Rothenberg, KA | 1 |
| Suarez, P | 1 |
| Ho, TV | 1 |
| Mell, MW | 2 |
| Xu, B | 2 |
| Curtin, CM | 1 |
| Yu, X | 1 |
| Jiang, D | 1 |
| Wang, J | 1 |
| Wang, R | 1 |
| Chen, T | 1 |
| Wang, K | 1 |
| Durgahee, MSA | 1 |
| Wei, X | 1 |
| Cao, S | 1 |
| Fujimura, N | 1 |
| Xiong, J | 1 |
| Kettler, EB | 1 |
| Xuan, H | 1 |
| Glover, KJ | 1 |
7 reviews available for metformin and Abdominal Aortic Aneurysm
| Article | Year |
|---|---|
Editor's Choice - Association Between Metformin Prescription and Abdominal Aortic Aneurysm Growth and Clinical Events: a Systematic Review and Meta-Analysis.
Topics: Aortic Aneurysm, Abdominal; Humans; Hypoglycemic Agents; Metformin | 2021 |
Research advances in drug therapy for abdominal aortic aneurysms over the past five years: An updated narrative review.
Topics: Anti-Bacterial Agents; Aortic Aneurysm, Abdominal; Aortic Rupture; Humans; Hydroxymethylglutaryl-CoA | 2023 |
Research advances in drug therapy for abdominal aortic aneurysms over the past five years: An updated narrative review.
Topics: Anti-Bacterial Agents; Aortic Aneurysm, Abdominal; Aortic Rupture; Humans; Hydroxymethylglutaryl-CoA | 2023 |
Research advances in drug therapy for abdominal aortic aneurysms over the past five years: An updated narrative review.
Topics: Anti-Bacterial Agents; Aortic Aneurysm, Abdominal; Aortic Rupture; Humans; Hydroxymethylglutaryl-CoA | 2023 |
Research advances in drug therapy for abdominal aortic aneurysms over the past five years: An updated narrative review.
Topics: Anti-Bacterial Agents; Aortic Aneurysm, Abdominal; Aortic Rupture; Humans; Hydroxymethylglutaryl-CoA | 2023 |
Relationship between metformin and abdominal aortic aneurysm.
Topics: Aortic Aneurysm, Abdominal; Humans; Hypoglycemic Agents; Metformin | 2020 |
Top 10 candidate aortic disease trials.
Topics: Aorta; Aortic Aneurysm, Abdominal; Aortic Dissection; Balloon Occlusion; Biomarkers; Clinical Trials | 2020 |
Abdominal aortic aneurysm: a review on the role of oral antidiabetic drugs.
Topics: Aortic Aneurysm, Abdominal; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agent | 2020 |
The Protective Effect of Metformin on Abdominal Aortic Aneurysm: A Systematic Review and Meta-Analysis.
Topics: Aortic Aneurysm, Abdominal; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; H | 2021 |
Metformin prescription and aortic aneurysm: systematic review and meta-analysis.
Topics: Aortic Aneurysm, Abdominal; Aortic Rupture; Diabetes Mellitus; Disease Progression; Drug Prescriptio | 2019 |
2 trials available for metformin and Abdominal Aortic Aneurysm
| Article | Year |
|---|---|
Protocol for the Metformin Aneurysm Trial (MAT): a placebo-controlled randomised trial testing whether metformin reduces the risk of serious complications of abdominal aortic aneurysm.
Topics: Aortic Aneurysm, Abdominal; Australia; COVID-19; Humans; Metformin; Pandemics; Prospective Studies; | 2021 |
The Metformin for Abdominal Aortic Aneurysm Growth Inhibition (MAAAGI) Trial.
Topics: Aortic Aneurysm, Abdominal; Disease Progression; Female; Humans; Male; Metformin; Multicenter Studie | 2021 |
17 other studies available for metformin and Abdominal Aortic Aneurysm
| Article | Year |
|---|---|
Impact of Metformin Treatment on Outcomes after Abdominal Aortic Aneurysm Repair.
Topics: Aortic Aneurysm, Abdominal; Endovascular Procedures; Humans; Metformin; Treatment Outcome | 2022 |
Metformin therapy is not associated with the lower prevalence of ascending aortic aneurysm in diabetic patients.
Topics: Animals; Aortic Aneurysm; Aortic Aneurysm, Abdominal; Aortic Valve; Diabetes Mellitus; Humans; Metfo | 2022 |
Metformin protects against abdominal aortic aneurysm by Atg7-induced autophagy.
Topics: Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Autophagy; Autophagy-Related Protein 7; Disea | 2022 |
Optimal Timing of Surveillance Ultrasounds in Small Aortic Aneurysms.
Topics: Aged; Aortic Aneurysm, Abdominal; Female; Humans; Male; Metformin; Retrospective Studies; Risk Facto | 2022 |
Association between metformin and abdominal aortic aneurysm in diabetic and non-diabetic US veterans.
Topics: Aged; Aortic Aneurysm, Abdominal; Comorbidity; Diabetes Mellitus; Humans; Male; Metformin; Models, B | 2020 |
Metformin Prescription Associated with Reduced Abdominal Aortic Aneurysm Growth Rate and Reduced Chemokine Expression in a Swedish Cohort.
Topics: Aged; Aortic Aneurysm, Abdominal; Biomarkers; Case-Control Studies; Chemokines; Diabetes Mellitus, T | 2021 |
Reduced Abdominal Aortic Aneurysm Growth Rate in Diabetic Patients Treated by Metformin: A Potential Role of Chemokines?
Topics: Aortic Aneurysm, Abdominal; Chemokines; Diabetes Mellitus; Humans; Metformin; Treatment Outcome | 2021 |
Metformin Inhibits Abdominal Aortic Aneurysm Formation through the Activation of the AMPK/mTOR Signaling Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Dilatation, Pa | 2021 |
Association of Metformin and Abdominal Aortic Aneurysm Repair Outcomes.
Topics: Aged; Aortic Aneurysm, Abdominal; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Male; Metf | 2021 |
Metformin to Limit Abdominal Aortic Aneurysm Expansion: Time for Clinical Trials.
Topics: Aortic Aneurysm, Abdominal; Aortic Rupture; Humans; Hypoglycemic Agents; Metformin | 2021 |
Metformin treatment does not affect the risk of ruptured abdominal aortic aneurysms.
Topics: Aged; Aged, 80 and over; Aortic Aneurysm, Abdominal; Aortic Rupture; Case-Control Studies; Denmark; | 2017 |
Association between metformin prescription and growth rates of abdominal aortic aneurysms.
Topics: Aged; Aortic Aneurysm, Abdominal; Cohort Studies; Diabetes Mellitus; Female; Humans; Hypoglycemic Ag | 2017 |
Metformin and Abdominal Aortic Aneurysm.
Topics: Aortic Aneurysm, Abdominal; Humans; Hypoglycemic Agents; Metformin | 2017 |
Metformin does not reduce inflammation in diabetics with abdominal aortic aneurysm or at high risk of abdominal aortic aneurysm formation.
Topics: Aortic Aneurysm, Abdominal; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cytokines; | 2018 |
Editor's Choice - Metformin Prescription is Associated with a Reduction in the Combined Incidence of Surgical Repair and Rupture Related Mortality in Patients with Abdominal Aortic Aneurysm.
Topics: Aged; Aged, 80 and over; Aortic Aneurysm, Abdominal; Aortic Rupture; Australia; Cohort Studies; Cost | 2019 |
Metformin prescription status and abdominal aortic aneurysm disease progression in the U.S. veteran population.
Topics: Aged; Aortic Aneurysm, Abdominal; Databases, Factual; Diabetes Mellitus, Type 2; Disease Progression | 2019 |
Metformin treatment status and abdominal aortic aneurysm disease progression.
Topics: Administration, Oral; Aged; Animals; Aortic Aneurysm, Abdominal; California; Data Mining; Databases, | 2016 |